Dublin, Dec. 05, 2023 – According to a report titled “Acute Myeloid Leukemia (AML) Therapeutics – Global Strategic Business Report” by ResearchAndMarkets.com, the global market for AML therapeutics is expected to reach $1.6 billion by 2030. The market, estimated at $587.6 million in 2022, is projected to grow at a CAGR of 13.4% over the analysis period 2022-2030. Cytarabine is one of the segments analyzed in the report and is projected to record a CAGR of 15.6%, reaching $571.6 million by the end of the analysis period. Additionally, the report highlights that the U.S. market for AML therapeutics is estimated to be $217.3 million in 2022, while China is forecast to grow at a CAGR of 15.4% and reach $151 million by 2030.
The report also provides insights into key market trends and drivers. Factors such as the high incidence and prevalence of AML, the expanding elderly population worldwide, advancements in pharmacology and molecular biology, and rising investments in AML therapeutics R&D are driving the growth of the market. However, chemotherapy complications may hinder market growth.
The COVID-19 pandemic has also had an impact on AML therapeutics. Delays caused by the pandemic have affected AML patients, and pandemic-related issues have affected oncology research. Despite these challenges, the market is primed for massive growth due to rising patient counts and promising research efforts. Key players in the market include Amgen, Astellas Pharma, AbbVie, and Aptose Biosciences.
For more information about the report, visit https://www.researchandmarkets.com.
About ResearchAndMarkets.com:
ResearchAndMarkets.com is a leading source for international market research reports and market data. They provide the latest data on international and regional markets, key industries, top companies, new products, and trends.
